Video

Terri E. Weaver, PhD, RN, on Efficacy of Solriamfetol for Treating Symptoms of Obstructive Sleep Apnea

01/14/2021

In this video, Terri E. Weaver, PhD, RN, talks about the effectiveness of solriamfetol in improving daily functioning, reducing daytime sleepiness, and enhancing work productivity.

Additional Resource:

Terri E. Weaver, PhD, RN, is dean and professor in the Department of Behavioral Nursing Science in the College of Nursing and professor in the Division of Pulmonary, Critical Care, Sleep, and Allergy in the Department of Medicine in the College of Medicine at the University of Illinois at Chicago.

TRANSCRIPT:

My name is Terri Weaver, I am Dean and professor at the University of Illinois Chicago College of Nursing.

This was a study to look at the effectiveness as opposed to the efficacy of solriamfetol with particular outcomes of daily functioning, daytime sleepiness, and also work productivity, along with perception of change by the patient and also the clinician.

It is approved for daytime sleepiness and patients with obstructive sleep apnea. It’s also approved for the treatment of sleepiness and narcolepsy. It is approved for 3 doses—75 mg, 150 mg, and 300 mg.

The findings showed that when this was evaluated, especially with a withdrawal phase that included a placebo, that the efficacy of solriamfetol was maintained long term, 40 weeks out.

So, the initial studies with clinical trial that was done to prove efficacy of solriamfetol showed that it was efficacious for daytime sleepiness, daily functioning, and work productivity. This study showed that efficacy was maintained long term, which was clinical effectiveness. And so, it has both efficacy and effectiveness

A component of the study was a withdrawal phase where individuals who were on doses that treated their sleepiness, when you withdrew that, in fact, they were still able to see the benefit in several outcomes that were the case with regard to the initial evaluation of the agent and that those who were placed on placebo during that time had a decline.

Thank you for the opportunity to share our work, greatly appreciate it.

Related Content

Mental Health
Mental Health
Esben Agerbo, DrMedSc, on Polygenic Risk Scores, When Used With Other Risk Factors, May Help Predict MDD
01/28/2021
The polygenic risk score (PRS) for depression may help identify major depressive disorder when considered along with other risk factors for depression, researchers recently reported in JAMA Psychiatry. ...
01/28/2021
Gastroenterology
aibd
Gastroenterology
Patient Engagement: How do we get our patients to work with us in their care?
08/17/2018
08/17/2018
Cardiovascular Diseases
Seth Baum, MD
Cardiovascular Diseases
Seth Baum, MD, on the Prevalence, Diagnosis, and Management of NASH and CVD
08/03/2016
In this video, Cardiology Consultant Advisory Board Member Seth Baum, MD, overviews the intersection between nonalcoholic steatohepatitis and cardiovascular disease, which he calls the "next big threat to...
08/03/2016
Mental Health
Mental Health
Expanding Patient Services Using Telehealth
03/18/2021
In this video, W. Clay Jackson, MD, DipTh, talks about expanding medical services to patients during the COVID-19 pandemic using telehealth, including using scales and screeners during patient telehealth...
03/18/2021
Diabetes
Daniel Einhorn, MD
Diabetes
CRS 2015: Single, Double, Triple and When to Use Newer Therapies for Diabetes
09/28/2015
Co-Chair Daniel Einhorn, MD, FACP, FACE, talks with fellow Co-Chair Edward Shahady, MD, FAAFP, ABCL about the early results of SGLT2 inhibitors and the cardiovascular benefits and cardiac outcomes.
09/28/2015